Formosa Pharmaceuticals

4:30 PM - 4:45 PM, Monday, June 3, 2019 ・ Theater 4
Formosa Laboratories offers full-service Antibody-Drug Conjugate manufacturing from antibody production (through domestic alliance), to in-house toxin-linker CMC services and antibody bioconjugation, and finally through to cytotoxic fill-finish drug product manufacturing. To demonstrate our capabilities, Formosa Laboratories is developing a biosimilar of ado-trastuzumab emtansine (Kadcyla), which is available for co-development or out-licensing. Historically, Formosa Laboratories, Inc. produces APIs and UV-filters in its state-of-the-art facilities near Taipei. Its GMP compliance has been approved by DOH of Taiwan, US FDA, BGV of Germany, EDQM and PMDA of Japan. Formosa’s major API products include Vitamin D derivatives. As a major producer in the world, our UV-filter products include avobenzone and Octinoxate. We also provide custom synthesis service from process development to full commercial production for APIs and other specialty chemicals, with full documentation support.
Ticker:
4746
Exchange:
Taiwan
Company Type:
Company HQ State:
Not Provided.
Company HQ Country:
Taiwan
Year Founded:
Not Provided.
Main Therapeutic Focus:
Lead Product in Development:
Biosimilar ado-trastuzumab emtansine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
CEO
Formosa Pharmaceuticals, Inc